sirolimus
Description :
Sirolimus inhibits angiogenesis - a new candidate for combination therapy! Sirolimus, approved by the FDA for immunosuppression in transplant patients, is currently under investigation for cancer treatment.
Seller Info :
Iris Biotech GmbH